Focused CRISPR/KO and CRISPR/Act screens identify WWTR1 (TAZ) as a critical driver of resistance to dabrafenib in anaplastic thyroid cancer. The gene discussed is WWTR1; the disease is thyroid gland undifferentiated (anaplastic) carcinoma.